Germany · Delayed Price · Currency is EUR GenSight Biologics Statistics
Total Valuation
FRA:G49N has a market cap or net worth of EUR 19.15 million. The enterprise value is 37.89 million.
| Market Cap | 19.15M |
| Enterprise Value | 37.89M |
Important Dates
The next estimated earnings date is Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 174.08M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +77.81% |
| Shares Change (QoQ) | +17.94% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 12.26% |
| Float | 108.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.26 |
| PB Ratio | -0.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.51 |
| EV / Sales | 40.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -165.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -85.07% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 83.20% |
| Revenue Per Employee | 72,692 |
| Profits Per Employee | -1.16M |
| Employee Count | 16 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:G49N has paid 7,000 in taxes.
| Income Tax | 7,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -63.71% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.17 |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 219 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:G49N had revenue of EUR 945,000 and -15.12 million in losses. Loss per share was -0.13.
| Revenue | 945,000 |
| Gross Profit | 945,000 |
| Operating Income | -15.20M |
| Pretax Income | -15.11M |
| Net Income | -15.12M |
| EBITDA | -15.53M |
| EBIT | -15.20M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 270,000 in cash and 19.01 million in debt, giving a net cash position of -18.74 million.
| Cash & Cash Equivalents | 270,000 |
| Total Debt | 19.01M |
| Net Cash | -18.74M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -32.11M |
| Book Value Per Share | -0.24 |
| Working Capital | -22.91M |
Cash Flow
| Operating Cash Flow | -8.05M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,608.57% |
| Pretax Margin | -1,599.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:G49N does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -77.81% |
| Shareholder Yield | -77.81% |
| Earnings Yield | -78.96% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:G49N has an Altman Z-Score of -11.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.25 |
| Piotroski F-Score | 2 |